Discovery of a potent and selective Axl inhibitor in preclinical model-Reference-Cited by-同舟云学术

Discovery of a potent and selective Axl inhibitor in preclinical model

Published:2021-06 Issue: Volume:39 Page:116137
ISSN:0968-0896
Container-title:Bioorganic & Medicinal Chemistry
language:en
Short-container-title:Bioorganic & Medicinal Chemistry

Author:

Inoue Satoshi,Yamane Yoshinobu,Tsukamoto Shuntaro,Azuma Hiroshi,Nagao Satoshi,Murai Norio,Nishibata Kyoko,Fukushima Sayo,Ichikawa Kenji,Nakagawa Takayuki,Hata Sugi Naoko,Ito Daisuke,Kato Yu,Goto Aya,Kakiuchi Dai,Ueno Takashi,Matsui Junji,Matsushima Tomohiro

Funder

Eisai Co Ltd

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference23 articles.

1. Key roles of AXL and MER receptor tyrosine kinases in resistance to multiple anticancer therapies;Schoumacher;Curr Oncol Rep,2017

2. AXL Inhibition sensitizes mesenchymal cancer cells to antimitotic drugs;Wilson;Cancer Res,2014

3. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype–specific therapeutic target for ovarian cancer;Antony;Sci Signal,2016

4. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer;Zhang;Nat Genet,2012

5. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib;Giles;Mol Cancer Ther,2013

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of Dual MER/AXL Kinase Inhibitors as Bifunctional Small Molecules for Inhibiting Tumor Growth and Enhancing Tumor Immune Microenvironment;Journal of Medicinal Chemistry;2024-06-24

2. Structure-activity relationship study of 1,6-naphthyridinone derivatives as selective type II AXL inhibitors with potent antitumor efficacy;European Journal of Medicinal Chemistry;2024-02

3. Structure-based drug discovery of novel fused-pyrazolone carboxamide derivatives as potent and selective AXL inhibitors;Acta Pharmaceutica Sinica B;2023-12

4. ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs;Molecular Cancer Therapeutics;2022-10-22

5. Two-Front War on Cancer—Targeting TAM Receptors in Solid Tumour Therapy;Cancers;2022-05-18